Clinical trials: Immune Related Disorder
HIV Infections
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3.
- Trial name
- NCT00000692
- Testing
- Butyldeoxynojirimycin
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- G D Searle
Lymphoma, Mantle-Cell
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT03647124
- Testing
- Lenalidomide
- Where
- 79 sites in Austria, France and 5 more
- Volunteers
- 105 people
- Sponsor
- Celgene
Poor Thymic Function, Immunodeficiency
Expanded Access Protocol Thymus Transplantation
The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation.
- Conditions
- Poor Thymic Function, Immunodeficiency, Athymia, Immunoreconstitution
- Trial name
- NCT02274662
- Testing
- Cultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
- Volunteers
- 11 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
HIV Infections
The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection
The objective of this clinical trial is to determine whether long-term oral dosage of ribavirin delays development of symptomatic HIV disease in HIV antibody positive subjects who are completely asymptomatic (CDC classification…
- Trial name
- NCT00002298
- Testing
- Ribavirin
- Sponsor
- ICN Pharmaceuticals
Macular Degeneration
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult…
- Trial name
- NCT00220805
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Grifols Therapeutics LLC
HIV Infections, Condyloma Acuminata
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection.
- Trial name
- NCT00002327
- Testing
- Cidofovir
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Sarcoma, Kaposi, HIV Infections
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
To determine the effect of Viracept in combination with modified antiretroviral therapy on the outcome of cutaneous and mucosal Kaposi's Sarcoma (KS).
- Trial name
- NCT00002185
- Testing
- Nelfinavir mesylate
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Agouron Pharmaceuticals
Birch Pollen-related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Study of rBet v1 Tablets
The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.
- Trial name
- NCT00901914
- Testing
- rBet v 1
- Where
- 8 sites in Denmark, Finland and 6 more
- Volunteers
- 483 people
- Sponsor
- Stallergenes Greer
HIV Infections
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
- Trial name
- NCT00002123
- Testing
- Delavirdine mesylate, Didanosine
- Where
- 84 sites in United States, Puerto Rico
- Sponsor
- Pharmacia and Upjohn
HIV Infections
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.
- Trial name
- NCT00002020
- Testing
- Zidovudine
- Where
- 12 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
- Trial name
- NCT00002394
- Testing
- Terbinafine hydrochloride
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis
HIV Infections
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in HIV-positive patients.
- Trial name
- NCT00002124
- Testing
- Delavirdine mesylate, Lamivudine, Zidovudine
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,250 people
- Sponsor
- Pharmacia and Upjohn
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
HIV Infections
A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines
The purpose of this study is to see if it is safe and effective to give AIDSVAX B/B or AIDSVAX B/E, two potential HIV vaccines, to HIV-negative volunteers.
- Trial name
- NCT00002402
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, Aluminum hydroxide
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VaxGen
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Pneumonia, Pneumocystis Carinii, HIV Infections
A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
Evaluate the effectiveness rate of dapsone plus trimethoprim as a therapy for the first episode of Pneumocystis carinii pneumonia (PCP) in AIDS patients.
- Trial name
- NCT00002283
- Testing
- Trimethoprim, Sulfamethoxazole, Dapsone
- Where
- United States
- Sponsor
- Jacobus Pharmaceutical
HIV Infections
Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate…
- Trial name
- NCT00002012
- Testing
- Interferon alfa-n3
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Interferon Sciences
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir
To evaluate the safety and efficacy of foscarnet induction treatment of cytomegalovirus (CMV) retinitis in AIDS patients who have previously suffered severe dose-limiting ganciclovir-related myelosuppression, who are ineligible…
- Trial name
- NCT00002301
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
HIV Infections, HIV Seronegativity
Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.
- Trial name
- NCT00002231
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
- Trial name
- NCT06668181
- Testing
- Bimekizumab
- Where
- 23 sites in Canada, France and 4 more
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL